Argitalpenak (16) MARÍA ARANZAZU AIS LARISGOITIA argitalpenak

2024

  1. Experience of patients with immune-mediated inflammatory diseases seen in a multidisciplinary integrated care unit

    Journal of Healthcare Quality Research, Vol. 39, Núm. 5, pp. 283-290

  2. Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study

    Farmacia Hospitalaria

2023

  1. Medicamentos inmunosupresores y biológicos en el embarazo, la lactancia y la fertilidad en enfermedades inmunomediadas

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 1, pp. 39-49

2022

  1. Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare

    Frontiers in Immunology, Vol. 13

  2. Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 47, Núm. 12, pp. 2020-2029

  3. Implementation and evaluation of a home pharmaceutical care model through Telepharmacy

    Farmacia Hospitalaria, Vol. 46, pp. 36-46

  4. Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey

    Journal of medical Internet research, Vol. 24, Núm. 9, pp. e37445

  5. The Characteristics and Functionalities of Mobile Apps Aimed at Patients Diagnosed With Immune-Mediated Inflammatory Diseases: Systematic App Search

    Journal of Medical Internet Research, Vol. 24, Núm. 3

2016

  1. Antiinfecciosos vía general

    Medimecum 2016: guía de terapia farmacológica ([Madrid] : Springer), pp. 559-728

  2. Antiparasitarios

    Medimecum 2016: guía de terapia farmacológica ([Madrid] : Springer), pp. 1073-1091

2013

  1. Equipotent doses of pegylated epoetin β (CERA) for the treatment of outcome patients with anemia secondary to chronic kidney disease in clinical practice

    Atencion Farmaceutica, Vol. 15, Núm. 1, pp. 55-58

  2. Information leaflets for patients with hepatitis C receiving treatment with triple therapy

    European Journal of Hospital Pharmacy, Vol. 20, Núm. 1, pp. 13-19

  3. Nuevos tratamientos para la esclerosis múltiple

    Medicina Clinica, Vol. 140, Núm. 2, pp. 76-82

  4. Permanencia del tratamiento antirretroviral de última generación en la práctica clínica diaria

    Farmacia Hospitalaria, Vol. 37, Núm. 2, pp. 151-155

2011

  1. Evolution of adherence to antiretroviral treatment in a spanish hospital during 2001, 2005 and 2008

    Latin American Journal of Pharmacy, Vol. 30, Núm. 6, pp. 1173-1178

  2. Indicación de uso de los antirretrovirales de última generación en la práctica clínica actual

    Farmacia Hospitalaria, Vol. 35, Núm. 1, pp. 14-22